Apolipoprotein E genetic variation and statin therapy appointment

Kassenova, A.; Kossumov, A.; Nurgozhin, T.; Supiyev, A.

dc.contributor.author	Kassenova, A.
dc.contributor.author	Kossumov, A.
dc.contributor.author	Nurgozhin, T.
dc.contributor.author	Supiyev, A.
dc.date.accessioned	2016-05-30T05:10:29Z
dc.date.available	2016-05-30T05:10:29Z
dc.date.issued	2016-05
dc.identifier.citation	A. Kassenova, A. Kossumov, T. Nurgozhin, and A. Supiyev. 2016. Apolipoprotein E genetic variation and statin therapy appointment. Abstract book. 4 th International Scientific Conference “Regenerative medicine & healthy aging”. National Laboratory Astana, Nazarbayev University. http://nur.nu.edu.kz/handle/123456789/1503	ru_RU
dc.identifier.uri	http://nur.nu.edu.kz/handle/123456789/1503
dc.description.abstract	Dyslipidemia is an important risk factor for cardiovascular disease due to the significant influence of cholesterol on atherosclerosis. Several genetic variants in genes related with triglyceride (TG) metabolism has been described, including LPL, apolipoprotein A5 and apolipoprotein E (Apo E) are associated with dyslipidemia by involvement to lipid metabolism. The combined analysis of these polymorphisms could produce clinically meaningful complementary information. Changes in TG levels are now considered an independent cardiovascular risk factor; hence, the study of combined variants in genes involved in TG metabolism may help explain part of the risk for CVD. The most informative polymorphisms within the Apo E gene are the Arg158Cys (rs7412) and Cys112Arg (rs429358) which define Apo E gene alleles, epsilon2, 3 and 4 (£2, £3 and £4).	ru_RU
dc.language.iso	en	ru_RU
dc.rights	Attribution-NonCommercial-ShareAlike 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/3.0/us/	*
dc.subject	Dyslipidemia	ru_RU
dc.subject	apolipoprotein	ru_RU
dc.subject	genotype	ru_RU
dc.subject	statin therapy	ru_RU
dc.title	Apolipoprotein E genetic variation and statin therapy appointment	ru_RU
dc.type	Abstract	ru_RU